Breaking News

FDA Fully Approves Precigen’s Papzimeos

Papzimeos is the first and only approved therapy to treat adults with Recurrent Respiratory Papillomatosis.

By: Rachel Klemovitch

Assistant Editor

Precigen, Inc., a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, announced that the US Food and Drug Administration (FDA) has approved Papzimeos (zopapogene imadenovec-drba) to treat adults with recurrent respiratory papillomatosis (RRP). This is the first and only FDA-approved therapy to treat adults with RRP.  Precigen completed submission of the rolling Biologics License Application (BLA) in December 2024 under ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters